Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05726747 · ClinicalTrials.gov registry record
QOL and Sarcopenia in Patients With Ascites
A clinical trial of Ascites Hepatic and Ascites, Malignant, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT05726747: Recruiting study of Ascites Hepatic and Ascites, Malignant, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05726747 is a study of Ascites Hepatic and Ascites, Malignant that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 70 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05726747, a study of Ascites Hepatic and Ascites, Malignant, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Clinical data regarding quality of life in patients with refractory ascites is limited and preceded the development of newer questionnaires that may be more robust. One primary objective of this study is to study changes in quality in life in a prospective fashion using newer general and ascites-specific quality of life survey instruments specific to benign and malignant etiologies. Sarcopenia is a condition that is prevalent in cancer and cirrhosis. Current data is retrospective and associative, evaluating heterogeneous patient populations at different stages within the timeline of refractory ascites. The other primary objective of this study is to study sarcopenia in a prospective fashion and to understand its kinetics once a patient develops refractory ascites. Prospectively-obtained measures of deterioration in patient-reported outcomes and in muscle mass will form the basis for the next stage of investigation of interventions to mitigate these declines.
Primary Outcome
Patient-Reported Outcomes Measurement Information System (PROMIS-10) survey scores physical and mental health on a 4-20 point scale which are combined into an overall score with higher scores reflecting better quality of life.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Quality of Life surveys
Study Locations (1)
Pennsylvania
- University of Pennsylvania Perelman School of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2026-10 |
What NCT05726747 shows while recruiting
NCT05726747 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target.
The record links to 2 conditions, with Ascites Hepatic appearing as the primary indexed condition, and to 1 intervention - of which Quality of Life surveys is the first listed.
NCT05726747 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05726747 about?
NCT05726747 is a clinical study titled "QOL and Sarcopenia in Patients With Ascites". Clinical data regarding quality of life in patients with refractory ascites is limited and preceded the development of newer questionnaires that may be more robust. One primary objective of this study is to study changes in quality in life in a prospective fashion using newer general and ascites-spe...
What is the current status of trial NCT05726747?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2023-05-23. Estimated completion is 2026-10.
What conditions does trial NCT05726747 study?
This clinical trial studies the following conditions: Ascites Hepatic, Ascites, Malignant.
What interventions are being tested in trial NCT05726747?
The interventions under investigation include: Quality of Life surveys (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05726747?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05726747 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ascites Hepatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI